

## **IDEX Biometrics ASA – Contemplated Private Placement**

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.**

Oslo, Norway, 4 December 2025

IDEX Biometrics ASA ("IDEX" or the "Company") announces a contemplated private placement of up to NOK 20 million (the "Private Placement") by issuance of up to 6,666,666 new shares (the "Offer Shares") in the Company. The subscription price is NOK 3 per Offer Share (the "Offer Price").

Anders Storbråten (privately and through Altea AS), Robert Keith, Morten Opstad and Kjell-Arne Besseberg have pre-indicated that they will subscribe for approx. NOK 6 million, NOK 5.8 million, NOK 0.5 million and NOK 0.15 million, respectively, in the Private Placement. The Company has received indications exceeding the Private Placement in pre-sounding.

The net proceeds from the Private Placement will be used to accelerate time to profitability, working capital needs, as well as capital expenditures and other general corporate purposes.

The Offer Price has been determined by the Company's board of directors (the "Board"). The Offer Shares will be issued pursuant to an authorization to issue new shares granted to the Board by the extraordinary general meeting held on 14 August 2025 (the "Authorization").

### **The Application Period**

The application period for the Private Placement will commence today, 4 December 2025 at 16:30 CET and is expected to close no later than 5 December 2025 at 08:00 CET (the "Application Period"). The Company reserves the right to at any time and in its sole discretion resolve to close or extend the Application Period or to cancel the Private Placement in its entirety without further notice. If the Application Period is shortened or extended, any other dates referred to herein may be amended accordingly.

The Private Placement will be divided into two tranches. Tranche 1 ("Tranche 1") will consist of up to 5,690,970 Offer Shares, which may be issued pursuant to the Authorization and Tranche 2 ("Tranche 2") will consist of 975,696 Offer Shares, subject to approval by an extraordinary general meeting, expected to be held end of December/January 2025 (the "EGM"). Anders Storbråten (privately and through Altea AS) has agreed to be allocated Offer Shares in Tranche 2 of the Private Placement.

#### Conditions for completion of the Private Placement

Completion of the Private Placement is subject to (i) the Board resolving to consummate the Private Placement and allocate the Offer Shares, as well as approval of ancillary resolutions necessary to consummate the Private Placement, and (ii) registration of the share capital increase pertaining to issue of the Offer Shares in the Norwegian Register of Business Enterprises. The conditions described above are jointly referred to as the "Conditions".

Completion of Tranche 1 is not conditional upon completion of Tranche 2, and acquisition of shares in Tranche 1 will remain final and binding and cannot be revoked or terminated by the respective applicants if Tranche 2 is not completed. The Applicant acknowledges that Tranche 1 and Tranche 2 of the Private Placement will be cancelled if the Conditions are not fulfilled and that the Board reserves the right to cancel, and/or modify the terms of the Private Placement, at any time and for any reason prior to delivery of the Offer Shares in Tranche 1, without or on short notice. Neither the Company nor any of its advisors will be liable for any losses if the Private Placement is cancelled or modified, irrespective of the reason for such cancellation or modification.

#### Allocation

The final number of Offer Shares will be determined at the end of the Application Period, and the final allocation will be made at the sole discretion of the Board. The allocation will be based on criteria such as (but not limited to) timeliness of the application, relative order size, sector knowledge, investment history, perceived investor quality and investment horizon. The Board may, at its sole discretion, reject and/or reduce any applications. There is no guarantee that any applicant will be allocated Offer Shares. Notification of allotment and payment instructions is expected to be issued to the applicants on or about 5 December 2025 through a notification to be issued by the settlement agent.

#### Settlement and payment

The payment date for the Offer Shares will be 9 December 2025. The Offer Shares will be delivered to investors and become tradable on the Oslo Stock Exchange once the share capital increase has been duly registered with the Norwegian Register of Business Enterprises. Such registration will take place following receipt of the full subscription amount from all participating investors. The Offer Shares are expected to be delivered on or about 11 December 2025, subject to the timely payment by investors.

#### Selling restrictions

The Private Placement will be directed towards Norwegian and international investors, subject to applicable exemptions from relevant registration, filing and prospectus requirements, and subject to other applicable selling restrictions. The minimum application and allocation amount has been set to the NOK equivalent of EUR 100,000. The Company may however, at its sole discretion, allocate amounts below EUR 100,000 to the extent exemptions from the prospectus requirements in accordance with applicable regulations, including the Norwegian Securities Trading Act and ancillary regulations, are available. Further selling restrictions and transaction terms will apply.

#### Equal treatment of shareholders

The Board has considered the contemplated Private Placement in light of the equal treatment obligations under the Norwegian Securities Trading Act and Oslo Børs' Circular no. 2/2014 and deems that the proposed Private Placement would be in compliance with these requirements. The Board holds the view that it will be in the common interest of the Company and its shareholders to raise equity through a private placement, in view of the current market conditions and the growth opportunities currently available to the Company. A private placement enables the Company to raise capital in an efficient manner, and the Private Placement is structured to ensure that a market-based subscription price is achieved. In order to limit the dilutive effect of the Private Placement and to facilitate equal treatment, the Board will consider carrying out a subsequent offering directed towards shareholders who did not participate in the Private Placement (see details below).

#### The Subsequent Offering

Subject to among other things (i) completion of the Private Placement, (ii) relevant corporate resolutions including approval by the Board and an extraordinary general meeting, (iii) the prevailing market price of IDEX's shares being higher than the Offer Price, IDEX will consider whether to carry out a subsequent offering (the "Subsequent Offering") of new shares in the Company. A Subsequent Offering will, if made, be directed towards existing shareholders in the Company as of 4 December 2025, as registered in IDEX's register of shareholders with Euronext Securities Oslo, the central securities depository in Norway (Nw. Verdipapirsentralen) (the "VPS") two trading days thereafter, who (i) are not allocated Offer Shares in the Private Placement, and (ii) are not resident in a jurisdiction where such offering would be unlawful or would (other than Norway) require any prospectus, filing, registration or similar action (the "Eligible Shareholders"). The Eligible Shareholders are expected to be granted non-tradable subscription rights. If carried out, the subscription period in a Subsequent Offering is expected to commence shortly after publication of the Prospectus (if relevant), and the subscription price in the Subsequent Offering will be the same as the Offer Price in the Private Placement. IDEX will issue a separate stock exchange notice with further details on the Subsequent Offering if and when finally resolved.

#### Company update on dispute with Alta Consulting

The Company is in a dispute with Alta Consulting srl., a consulting company controlled by the former CEO of the Company, Catharina Eklöf, regarding the financial terms following the termination of the CEO. The amount under dispute is approx. NOK 8.5 mill plus interest. IDEX believes that it was entitled to terminate the agreement with immediate effect, and that the former CEO is not entitled to any further payments from the Company. The former CEO objects to the Company's position and has commenced legal proceedings against the Company for the Oslo City Court. Recent settlement negotiations have been unsuccessful.

#### About IDEX Biometrics ASA

IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our

**PRESS RELEASE**

04 December 2025 17:11:00 CET

biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to MAR article 17 and section 5 -12 of the Norwegian Securities Trading Act. This stock exchange release was published by Kjell-Arne Besseberg, Chief Operating Officer, at the time and date stated above.

**Important information:**

This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or its securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to "qualified institutional buyers" as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "EU Prospectus Regulation" means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

Matters discussed in this announcement may constitute forward-looking statements.

Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control.

Actual events may differ significantly from any anticipated development due to a number of factors, including without limitation, changes in investment levels and need for the Company's services, changes in the general economic, political and market conditions in the markets in which the Company operate, the Company's ability to attract, retain and motivate qualified personnel, changes in the Company's ability to engage in commercially acceptable acquisitions and strategic investments, and changes in laws and regulation and the potential impact of legal proceedings and actions. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not provide any guarantees that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on the forward-looking statements in this document.

The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.

Neither the Company's advisors nor any of their affiliates make any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. Neither the Company's advisors nor any of its affiliates accept any liability arising from the use of this announcement.



**PRESS RELEASE**

04 December 2025 17:11:00 CET

**Contacts**

Anders Storbråten, CEO and CFO, Tel: +47 416 38 582

E-mail: [ir@idexbiometrics.com](mailto:ir@idexbiometrics.com)

**Attachments**

[IDEX Company Update](#)